若生智能
Drug Database
VA

varicella zoster immunoglobulin (VariQuin)

✓ Approved

Prothya Biosolutions · 多克隆抗体 · 多克隆抗体

什么是 varicella zoster immunoglobulin？

varicella zoster immunoglobulin 是一种多克隆抗体，由Prothya Biosolutions研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intramuscular (IM) Injection。

药物档案

商品名VariQuin
公司Prothya Biosolutions
药物类别多克隆抗体, 细胞治疗, 抗体
给药途径Injectable (Others), Intramuscular (IM) Injection
状态Approved
来源： ClinicalTrials.gov, Prothya Biosolutions

治疗适应症

varicella zoster immunoglobulin 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsVaricella zoster virus infection✓ Approved

相关研究文献

PubMedFrontiers in immunology2026-08-05

Effectiveness of varicella vaccine during a varicella outbreak in a Chinese senior high school: a retrospective cohort study.

Xu Nani N, Wu Liting L, Deng Xuan X, Shu Xin X et al.

To evaluate the vaccine effectiveness (VE) of single-dose and two-dose varicella vaccine (VarV) among senior high school students during a varicella outbreak in China, and provide recommendations for vaccination strategy optimization. A retrospective cohort study was conducted among students in a senior high school in China during a varicella outbreak from July 23 to November 8, 2024. The history of varicella disease, the immunization history of VarV and the incidence during the outbreak among all students in the school were surveyed. Kaplan-Meier methods were used to estimate the cumulative varicella-free survival rate among students with different immunization histories during the outbreak, and the log-rank test was used to compare the survival curves across the five groups. VE was calculated based on attack rates among students with different vaccination doses and intervals since last vaccination. Post-exposure vaccination VE was also assessed. Logistic regression analysis was performed to identify factors associated with varicella infection during the outbreak, and odds ratio (OR) and 95% confidence interval (95% CI) were calculated. Among the 1,862 students present during the outbreak, the overall varicella attack rate was 6.29%. Kaplan-Meier analysis showed significant differences in cumulative varicella-free survival among the different immunization groups (χ² = 297.913, df = 4, P < 0.001). Single-dose varicella vaccine (VarV) coverage was 28.24% (475/1682), and two-dose coverage was 66.23% (1114/1682). Compared with unvaccinated individuals, VE with 95% CI was 32.14% (-54.37%- 70.17%) for 1-dose recipients and 94.74% (88.62%-97.57%) for 2-dose recipients. Among 1-dose recipients, VE was 90.48% (17.22%-98.90%) and 18.68% (-86.86%- 64.61%) for those with an immunization interval ≤10 years and >10 years, respectively. Among 2-dose recipients, VE was 95.94%(90.69%-98.23%) and 92.89%(83.87%-96.87%) for those with an immunization interval ≤6 years and >6 years, respectively. Logistic regression showed that male students had a higher risk of varicella than female students; prior receipt of two doses of VarV significantly reduced the risk of infection; and the risk increased by 1 year for each additional year between the last immunization and exposure to the index case. The VE of post-exposure vaccination was 90.15% (68.53%-96.92%) among unvaccinated students and 94.88% (89.47%-97.51%) among students who had previously received 1 dose. A single dose of varicella vaccine provides limited long-term protection among high school students, whereas a two-dose regimen offers robust and sustained effectiveness. Routine catch-up vaccination and timely post-exposure vaccination are recommended for the effective control of varicella outbreaks in school settings.

PMID 42553282
阅读全文 →
PubMedJournal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG2026-08-05

Atopic dermatitis is associated with herpes zoster in adults - A matched cohort study using electronic health records data in England.

Schober Anna K AK, Langan Sinéad M SM, Williams Hywel C HC, Forbes Harriet H et al.

Some atopic dermatitis (AD) treatments have been linked to an increased risk of herpes zoster (HZ). Limited evidence suggests an independent association between atopic dermatitis and herpes zoster. The study aimed to investigate the association between atopic dermatitis and herpes zoster in the UK and to explore the role of treatments in this relationship. We conducted a matched cohort study using routinely collected primary care data from the UK Clinical Practice Research Datalink (CPRD) Aurum database (1997-2023) and applied Cox regression models. Age, behavioral factors, several comorbid diseases and different treatment exposures were included as covariates. Individuals with atopic dermatitis had an adjusted hazard ratio of 1.28 (95% CI: 1.27-1.29) for HZ. Adjustments for different definitions of oral corticosteroid exposure as well as other traditional immunosuppressants led to minimal reductions in the association. The risk of herpes zoster increased with AD severity (aHR for mild AD: 1.22 [95% CI: 1.20-1.23]; aHR for moderate AD: 1.28 [95% CI: 1.27-1.30]; aHR for severe AD: 2.33 [95% CI: 2.22-2.45]). The risk of HZ is increased in individuals with atopic dermatitis, independent of comorbidities and the use of oral corticosteroids or immunosuppressants. This elevated baseline risk is particularly relevant because herpes zoster is also a known adverse effect of newer therapies such as Janus kinase (JAK) inhibitors. These findings may inform vaccination guidelines.

PMID 42552854
阅读全文 →
PubMedThe Pediatric infectious disease journal2026-08-05

Management of Invasive Group A Streptococcal Four Infections in Children: The European Society for Pediatric Infectious Disease Guidelines.

Chiappini Elena E, Pellegrino Roberta R, Dalpiaz Irene I, Renni Marco M et al.

Invasive group A streptococcal (iGAS) infections in children, although rare, are associated with significant morbidity and mortality, and their incidence has risen globally in recent years. Evidence for optimal management in children is limited. These guidelines aim to provide evidence-based recommendations for the management of pediatric iGAS, including antibiotic therapy, adjunctive nonantibiotic therapies and prophylaxis of close contacts. The ESPID Guidelines Committee convened a multidisciplinary working group. A systematic literature search of pediatric studies published from 2003 to 2023 in PubMed, Embase and the Cochrane Library was performed. Clinical questions with pediatric data were formulated as PICO and assessed using the GRADE approach, with consensus achieved through a modified Delphi process. For clinically important questions lacking sufficient evidence, narrative synthesis with nongraded expert consensus was used. Additional publications until August 2025 contributed qualitatively but were not formally GRADE-graded. Penicillins remain the first-line therapy for iGAS. In severe or toxin-mediated infections (eg, necrotizing fasciitis or streptococcal toxic shock syndrome), adjunctive clindamycin is suggested, with linezolid as an alternative where clindamycin resistance is confirmed or in central nervous system disease. Intravenous immunoglobulin may be considered in life-threatening toxin-mediated disease, whereas evidence for corticosteroids is insufficient. Prophylaxis is recommended for high-risk household contacts (neonates, postpartum women, elderly, immunocompromised, and recent varicella infection) and considered for all contacts in outbreak settings. These ESPID guidelines provide evidence-based recommendations for the management of pediatric iGAS. Given the rarity and limited trial data, most recommendations are weak and supported by low-quality evidence, highlighting the need for high-quality pediatric studies.

PMID 42552564
阅读全文 →
PubMedHIV/AIDS (Auckland, N.Z.)2026-08-05

From Denial to Near Blindness: Overcoming Herpes Zoster Ophthalmicus in a Rural Ugandan Man with HIV and Alcoholism.

Okongo Benson B, Amuge Gladys G, Adong Ruth Lucy RL, Okengo Anthony O AO et al.

In remote Ugandan settings, HIV care retention remains poor among men and pastoralists. Despite progress toward UNAIDS 95-95-95 targets, structural barriers, geographic isolation and stigma continue to undermine long-term retention. In 2022, a male pastoralist in his early forties with heavy alcohol use presented to a rural health center in Karamoja with fever and weight loss, and was diagnosed with HIV. He declined antiretroviral therapy (ART) believing the drugs were "poisonous" and was lost to follow-up for 48 months. He re-presented in March 2026 with a one-year history of a scaly, pruritic lesion on his right hand extending to the face and neck, unresponsive to antifungal creams. Two days prior, he developed an acutely painful vesicular eruption in the right V1 trigeminal distribution, along with oropharyngeal candidiasis. CD4 count was 120 cells/μL and urine TB LAM was positive, indicating disseminated tuberculosis. While LAM is highly suggestive and warrants immediate empirical treatment, definitive diagnosis of dissemination ideally requires clinical and radiological correlation. He was treated with oral acyclovir (800 mg five times daily for 10 days), topical acyclovir, ibuprofen, intensive-phase anti-TB therapy, and fluconazole (200 mg daily for 14 days). ART was deferred for two weeks to manage acute opportunistic infections and monitor for IRIS. At two weeks, the zoster lesions had crusted, oral candidiasis cleared, and pain reduced to 2/10. ART was initiated on day 14 with village health team support. At three months, he remained adherent with no new opportunistic infections. Delayed ART initiation caused years of preventable suffering. This case highlights the urgent need in low-income settings for community re-engagement strategies, integrated HIV/co-infection screening, point-of-care diagnostics, and culturally tailored care. As the patient stated: "I was sick, and now I am well. The science of HIV treatment is a miracle, and I am living proof.".

PMID 42553801
阅读全文 →
PubMedBiology open2026-08-05

Impacts of early-life thermal challenge on development, survival, and physiology in wild great tits.

Fleitz Julie J, Furic Clémence C, Davies Charli S CS, Palttala Jenna J et al.

Rapid climate change is increasing thermal extremes that may challenge developing endotherms. In altricial birds, early postnatal life is a sensitive period because thermoregulatory and physiological systems are still maturing. We experimentally manipulated nest temperature in a wild population of great tit to test whether mild, ecologically realistic heat (+2.3°C) and cold (-1.3°C) challenges affected development and physiology. Treatments were applied from days 2-8 post-hatching, and we measured growth, survival, hydration status (plasma osmolarity and uric acid), mitochondrial density, and immunoglobulin levels. Contrary to our predictions, thermal manipulation had no detectable effects on survival, morphology, or physiological traits at either day 8 or day 14. In contrast, all physiological markers varied significantly with age, reflecting normal osmoregulatory, metabolic, and immune development. These findings suggest that moderate, short-term thermal deviations during early development fall within the tolerance range of this population, or that parental behaviour buffered nestlings against temperature changes. However, stronger or prolonged extremes may exceed buffering capacity, and delayed effects cannot be excluded. Long-term studies are needed to assess latent fitness costs under increasingly variable climates.

PMID 42552904
阅读全文 →
PubMedClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2026-08-05

Processionary Moth Exposure in Europe: Toxic-Irritant and Immunoglobulin E-Mediated Endotypes, Diagnosis and Management.

Dasari Prasad P, Haas Josefine J, Rohe Wolfgang W, Gloyna Kai K et al.

Processionary moths (Thaumetopoea spp.), particularly the oak processionary moth (Thaumetopoea processionea), are an increasingly relevant cause of allergic and toxic disease in Europe, occurring in the context of reported range expansion, changing environmental conditions and persistent contamination with airborne urticating hairs (setae). Clinical manifestations range from toxic-irritant dermatitis and ocular injury to respiratory symptoms, while a subset of exposed individuals develops genuine IgE-mediated disease, including rhinoconjunctivitis, asthma, and rare cases of anaphylaxis. These presentations reflect two mechanistically distinct endotypes: (i) toxin-driven epithelial penetration by the urticating hairs with neuro-inflammatory activation and (ii) allergen-specific sensitisation to defined molecular components such as Tha p 1 and Tha p 2. Accurate endotype differentiation is clinically relevant, as symptom latency, severity, and risk of systemic progression differ substantially. Diagnostic evaluation relies on exposure history and phenotype recognition, complemented in selected cases and experienced centres by skin testing using research-grade extracts and emerging component-resolved approaches. Basophil activation testing may provide additional mechanistic insights in selected cases. Management comprises prompt decontamination, anti-inflammatory therapy, urgent ophthalmologic assessment when eye involvement is suspected, and guideline-based management of anaphylaxis. The environmental persistence of setae and recurrent seasonal exposure highlight the need for improved surveillance, validated molecular diagnostics, and translational research defining immune mechanisms and biomarkers.

PMID 42554243
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多varicella zoster immunoglobulin